Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection

NCT02589847 is registered in ClinicalTrials.gov with Rebiotix Inc. as lead sponsor.

NCT NCT02589847
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02589847 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Lead sponsor
Rebiotix Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2015
Completion date
March 31, 2019
Enrollment
272 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

clostridium difficile infection